Symbols / BTAI Stock $1.06 -3.64% BioXcel Therapeutics, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
BTAI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Vimal D. Mehta Ph.D.
Exch · Country NCM · United States
Market Cap 28.70M
Enterprise Value 109.94M
Income -69.90M
Sales 642.00K
FCF (ttm) -39.35M
Book/sh -4.28
Cash/sh 1.05
Employees 29
Insider 10d —
IPO Mar 08, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.64
PEG —
P/S 44.70
P/B -0.25
P/C —
EV/EBITDA -2.20
EV/Sales 171.25
Quick Ratio 0.53
Current Ratio 0.83
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -5.73
EPS next Y -1.65
EPS Growth —
Revenue Growth -30.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-26
Earnings (prior) 2026-03-26
ROA -75.47%
ROE —
ROIC —
Gross Margin 74.45%
Oper. Margin -40.16%
Profit Margin 0.00%
Shs Outstand 27.07M
Shs Float 24.67M
Insider Own 3.84%
Instit Own 15.37%
Short Float 14.89%
Short Ratio 3.99
Short Interest 3.95M
52W High 8.08
vs 52W High -86.88%
52W Low 1.01
vs 52W Low 4.95%
Beta 0.30
Impl. Vol. —
Rel Volume 0.32
Avg Volume 1.52M
Volume 489.65K
Target (mean) $14.00
Tgt Median $8.50
Tgt Low $1.00
Tgt High $38.00
# Analysts 4
Recom Buy
Prev Close $1.10
Price $1.06
Change -3.64%
About

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.00
Mean price target
2. Current target
$1.06
Latest analyst target
3. DCF / Fair value
$-26.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.06
Low
$1.00
High
$38.00
Mean
$14.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-02 main HC Wainwright & Co. Buy → Buy $5
2026-03-17 init Rodman & Renshaw — → Buy $17
2026-03-05 main HC Wainwright & Co. Buy → Buy $6
2025-09-15 reit HC Wainwright & Co. Buy → Buy $10
2025-09-12 main Mizuho Neutral → Neutral $4
2025-08-28 reit HC Wainwright & Co. Buy → Buy $10
2025-08-19 reit HC Wainwright & Co. Buy → Buy $10
2025-08-15 main HC Wainwright & Co. Buy → Buy $10
2025-07-15 reit LUCID CAPITAL MARKETS Buy → Buy $66
2025-06-23 main HC Wainwright & Co. Buy → Buy $8
2025-03-19 init Rodman & Renshaw — → Buy $65
2025-01-30 main HC Wainwright & Co. Buy → Buy $3
2025-01-07 down B of A Securities Buy → Underperform $0
2025-01-06 main Canaccord Genuity Buy → Buy $5
2024-10-21 main HC Wainwright & Co. Buy → Buy $5
2024-09-06 reit HC Wainwright & Co. Buy → Buy $7
2024-08-30 main Canaccord Genuity Buy → Buy $7
2024-08-09 main UBS Neutral → Neutral $1
2024-08-08 main HC Wainwright & Co. Buy → Buy $7
2024-06-27 main Canaccord Genuity Buy → Buy $7
News
RSS: Latest BTAI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 MEHTA VIMAL Chief Executive Officer — 383 — —
2026-03-13 YOCCA FRANK D. PH.D. Officer — 68 — —
2026-03-13 RODRIGUEZ JAVIER Officer — 68 — —
2026-03-13 STEINHART RICHARD I Chief Financial Officer — 68 — —
2025-12-15 MEHTA VIMAL Chief Executive Officer — 383 — —
2025-12-15 YOCCA FRANK D. PH.D. Officer — 68 — —
2025-12-15 RODRIGUEZ JAVIER Officer — 68 — —
2025-12-15 STEINHART RICHARD I Chief Financial Officer — 68 — —
2025-10-31 MACK DAVID J Director — 1,694 — —
2025-09-30 MACK DAVID J Director — 1,694 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.64
-71.67%
2.27
+64.20%
1.38
+268.00%
0.38
Operating Revenue
0.64
-71.67%
2.27
+64.20%
1.38
+268.00%
0.38
Cost Of Revenue
0.16
-92.35%
2.14
+70.08%
1.26
+6200.00%
0.02
Reconciled Cost Of Revenue
0.16
-92.35%
2.14
+70.08%
1.26
+6200.00%
0.02
Gross Profit
0.48
+288.62%
0.12
+2.50%
0.12
-66.20%
0.35
Operating Expense
50.74
-21.84%
64.93
-61.29%
167.74
+4.84%
160.00
Research And Development
30.25
-0.60%
30.43
-63.91%
84.33
-7.58%
91.24
Selling General And Administration
20.49
-40.58%
34.49
-58.65%
83.41
+21.31%
68.76
Selling And Marketing Expense
0.41
-70.70%
1.39
-88.87%
12.48
-4.01%
13.01
General And Administrative Expense
20.09
-39.32%
33.10
-53.33%
70.93
+27.21%
55.76
Salaries And Wages
6.26
-46.79%
11.76
-70.20%
39.46
+17.90%
33.47
Other Gand A
12.39
-37.04%
19.67
-33.82%
29.72
+49.25%
19.92
Total Expenses
50.91
-24.10%
67.07
-60.31%
169.00
+5.61%
160.02
Operating Income
-50.27
+22.43%
-64.80
+61.34%
-167.62
-4.99%
-159.65
Total Operating Income As Reported
-50.46
+24.96%
-67.25
+60.85%
-171.78
-7.60%
-159.65
EBITDA
-52.61
-19.14%
-44.16
+73.30%
-165.42
-5.22%
-157.22
Normalized EBITDA
-52.42
-25.64%
-41.72
+74.13%
-161.26
-2.57%
-157.22
Reconciled Depreciation
0.30
-2.91%
0.31
-2.83%
0.32
-2.75%
0.33
EBIT
-52.91
-18.99%
-44.47
+73.17%
-165.74
-5.20%
-157.54
Total Unusual Items
-0.19
+92.05%
-2.44
+41.36%
-4.16
0.00
Total Unusual Items Excluding Goodwill
-0.19
+92.05%
-2.44
+41.36%
-4.16
0.00
Special Income Charges
-0.19
+92.05%
-2.44
+41.36%
-4.16
0.00
Restructuring And Mergern Acquisition
0.19
-92.05%
2.44
-41.36%
4.16
0.00
Net Income
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Pretax Income
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Net Non Operating Interest Income Expense
-15.92
-27.07%
-12.53
-63.43%
-7.67
-34.83%
-5.68
Interest Expense Non Operating
16.98
+12.26%
15.13
+13.63%
13.31
+62.11%
8.21
Net Interest Income
-15.92
-27.07%
-12.53
-63.43%
-7.67
-34.83%
-5.68
Interest Expense
16.98
+12.26%
15.13
+13.63%
13.31
+62.11%
8.21
Interest Income Non Operating
1.07
-59.03%
2.60
-53.94%
5.65
+123.46%
2.53
Interest Income
1.07
-59.03%
2.60
-53.94%
5.65
+123.46%
2.53
Other Income Expense
-3.71
-120.93%
17.73
+570.47%
-3.77
-782.67%
-0.43
Other Non Operating Income Expenses
-3.52
-117.44%
20.17
+5020.05%
0.39
+192.27%
-0.43
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Net Income From Continuing Operation Net Minority Interest
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Net Income From Continuing And Discontinued Operation
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Net Income Continuous Operations
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Normalized Income
-69.70
-21.95%
-57.16
+67.32%
-174.89
-5.51%
-165.76
Net Income Common Stockholders
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Diluted EPS
-5.73
+75.63%
-23.51
+76.11%
-98.40
-3.89%
-94.72
Basic EPS
-5.73
+75.63%
-23.51
+76.11%
-98.40
-3.89%
-94.72
Basic Average Shares
12.21
+381.58%
2.54
+39.24%
1.82
+3.98%
1.75
Diluted Average Shares
12.21
+381.58%
2.54
+39.24%
1.82
+3.98%
1.75
Diluted NI Availto Com Stockholders
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Insurance And Claims
1.44
-13.58%
1.67
-4.13%
1.74
-26.46%
2.37
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
44.92
+17.16%
38.34
-47.98%
73.70
-64.20%
205.85
Current Assets
44.69
+19.50%
37.39
-48.17%
72.14
-64.44%
202.87
Cash Cash Equivalents And Short Term Investments
28.41
-4.82%
29.85
-54.23%
65.22
-66.33%
193.72
Cash And Cash Equivalents
28.41
-4.82%
29.85
-54.23%
65.22
-66.33%
193.72
Cash Financial
—
—
—
—
Receivables
0.23
+77.86%
0.13
+84.51%
0.07
-71.37%
0.25
Accounts Receivable
0.23
+77.86%
0.13
+84.51%
0.07
-71.37%
0.25
Inventory
0.72
+6.33%
0.68
-65.90%
1.99
+0.30%
1.99
Raw Materials
0.32
-37.35%
0.51
-45.88%
0.94
+37.10%
0.68
Work In Process
0.37
0.00
-100.00%
0.65
-8.05%
0.71
Finished Goods
0.04
-78.61%
0.17
-57.28%
0.41
-31.93%
0.59
Prepaid Assets
4.03
-23.86%
5.29
+90.15%
2.78
-9.29%
3.07
Restricted Cash
0.34
0.00
—
—
Other Current Assets
10.95
+660.07%
1.44
-30.70%
2.08
-45.93%
3.84
Total Non Current Assets
0.23
-75.53%
0.94
-39.45%
1.56
-47.77%
2.98
Net PPE
0.23
-73.05%
0.86
-41.78%
1.47
-28.54%
2.06
Gross PPE
2.03
-13.82%
2.36
-11.48%
2.67
-9.51%
2.94
Accumulated Depreciation
-1.80
-19.97%
-1.50
-25.90%
-1.19
-34.80%
-0.89
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.06
-85.34%
0.38
-44.48%
0.69
-29.51%
0.98
Machinery Furniture Equipment
0.78
+0.00%
0.78
+0.00%
0.78
-1.40%
0.79
Construction In Progress
—
—
—
0.00
Other Properties
—
—
—
0.98
Leases
1.20
+0.00%
1.20
+0.00%
1.20
+1.61%
1.18
Other Non Current Assets
—
0.09
+0.00%
0.09
-90.59%
0.93
Total Liabilities Net Minority Interest
140.38
+6.80%
131.44
+0.94%
130.21
+0.88%
129.08
Current Liabilities
53.93
+142.55%
22.23
-18.46%
27.27
-17.12%
32.90
Payables And Accrued Expenses
19.15
-12.27%
21.82
-18.44%
26.76
+2.43%
26.12
Payables
14.87
-8.14%
16.19
+16.65%
13.88
+29.30%
10.73
Accounts Payable
14.70
-8.06%
15.99
+17.11%
13.65
+33.50%
10.23
Current Accrued Expenses
4.28
-24.15%
5.64
-56.25%
12.88
-16.31%
15.39
Pensionand Other Post Retirement Benefit Plans Current
0.03
-2.86%
0.04
-78.53%
0.16
-97.44%
6.37
Total Tax Payable
0.03
-64.84%
0.09
-21.55%
0.12
+41.46%
0.08
Current Debt And Capital Lease Obligation
25.00
+6583.42%
0.37
+8.09%
0.35
+8.46%
0.32
Current Debt
24.93
—
—
—
Other Current Borrowings
24.93
—
—
—
Current Capital Lease Obligation
0.07
-82.62%
0.37
+8.09%
0.35
+8.46%
0.32
Other Current Liabilities
9.75
+2506.95%
0.37
+8.09%
0.35
-14.36%
0.40
Total Non Current Liabilities Net Minority Interest
86.45
-20.83%
109.21
+6.08%
102.94
+7.03%
96.18
Long Term Debt And Capital Lease Obligation
84.66
-17.46%
102.57
+1.52%
101.04
+7.67%
93.84
Long Term Debt
84.66
-17.41%
102.51
+1.90%
100.60
+8.11%
93.05
Long Term Capital Lease Obligation
0.00
-100.00%
0.07
-85.23%
0.44
-44.02%
0.79
Stockholders Equity
-95.46
-2.54%
-93.10
-64.76%
-56.51
-173.60%
76.78
Common Stock Equity
-95.46
-2.54%
-93.10
-64.76%
-56.51
-173.60%
76.78
Capital Stock
0.08
+55.10%
0.05
+63.33%
0.03
+7.14%
0.03
Common Stock
0.08
+55.10%
0.05
+63.33%
0.03
+7.14%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
22.33
+619.70%
3.10
+65.85%
1.87
+6.33%
1.76
Ordinary Shares Number
22.33
+619.70%
3.10
+65.85%
1.87
+6.33%
1.76
Additional Paid In Capital
624.55
+12.12%
557.05
+4.30%
534.06
+9.37%
488.29
Retained Earnings
-720.09
-10.75%
-650.20
-10.09%
-590.60
-43.51%
-411.55
Total Equity Gross Minority Interest
-95.46
-2.54%
-93.10
-64.76%
-56.51
-173.60%
76.78
Total Capitalization
-10.80
-214.81%
9.41
-78.66%
44.09
-74.04%
169.83
Working Capital
-9.24
-160.95%
15.16
-66.22%
44.88
-73.60%
169.97
Invested Capital
14.13
+50.22%
9.41
-78.66%
44.09
-74.04%
169.83
Total Debt
109.66
+6.91%
102.57
+1.52%
101.04
+7.67%
93.84
Net Debt
81.18
+11.73%
72.65
+105.37%
35.38
—
Capital Lease Obligations
0.07
+0.00%
0.07
-85.23%
0.44
-44.02%
0.79
Net Tangible Assets
-95.46
-2.54%
-93.10
-64.76%
-56.51
-173.60%
76.78
Tangible Book Value
-95.46
-2.54%
-93.10
-64.76%
-56.51
-173.60%
76.78
Derivative Product Liabilities
1.79
-73.01%
6.63
+248.19%
1.91
-18.69%
2.34
Dueto Related Parties Current
0.14
+28.97%
0.11
+0.00%
0.11
-74.64%
0.42
Interest Payable
—
0.00
-100.00%
0.74
-76.82%
3.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-57.62
+20.01%
-72.03
+53.53%
-155.01
-14.53%
-135.34
Cash Flow From Continuing Operating Activities
-57.62
+20.01%
-72.03
+53.53%
-155.01
-14.53%
-135.34
Net Income From Continuing Operations
-69.90
-17.28%
-59.60
+66.71%
-179.05
-8.02%
-165.76
Depreciation Amortization Depletion
0.30
-2.91%
0.31
-2.83%
0.32
-2.75%
0.33
Depreciation
0.30
-2.91%
0.31
-2.83%
0.32
-2.75%
0.33
Depreciation And Amortization
0.30
-2.91%
0.31
-2.83%
0.32
-2.75%
0.33
Other Non Cash Items
7.41
+1.31%
7.32
+107.08%
3.53
+82.30%
1.94
Stock Based Compensation
2.77
-55.05%
6.16
-66.93%
18.61
+7.37%
17.34
Operating Gains Losses
3.50
+117.37%
-20.18
-4528.44%
-0.44
-206.08%
0.41
Gain Loss On Investment Securities
3.50
+117.37%
-20.18
-4507.31%
-0.44
-212.60%
0.39
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.00
-90.91%
0.02
Change In Working Capital
-1.70
+71.77%
-6.03
-398.76%
2.02
-80.60%
10.40
Change In Receivables
-0.10
-70.00%
-0.06
-133.90%
0.18
+171.37%
-0.25
Changes In Account Receivables
-0.10
-70.00%
-0.06
-133.90%
0.18
+171.37%
-0.25
Change In Inventory
-0.04
-103.28%
1.31
+21966.67%
-0.01
+99.70%
-1.99
Change In Prepaid Assets
-8.16
-335.68%
-1.87
-164.82%
2.89
+173.96%
-3.90
Change In Payables And Accrued Expense
6.97
+237.72%
-5.06
-601.25%
-0.72
-104.29%
16.83
Change In Accrued Expense
0.00
+100.00%
-0.74
-129.48%
2.50
-34.36%
3.80
Change In Payable
6.97
+261.15%
-4.33
-34.42%
-3.22
-124.70%
13.03
Change In Account Payable
6.97
+261.15%
-4.33
-34.42%
-3.22
-124.70%
13.03
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
—
—
—
0.27
Change In Other Current Liabilities
-0.37
-8.09%
-0.35
-8.46%
-0.32
-8.87%
-0.29
Investing Cash Flow
0.00
0.00
+100.00%
-0.02
+85.61%
-0.14
Cash Flow From Continuing Investing Activities
0.00
0.00
+100.00%
-0.02
+85.61%
-0.14
Net PPE Purchase And Sale
0.00
0.00
+100.00%
-0.02
+85.61%
-0.14
Purchase Of PPE
0.00
0.00
+100.00%
-0.02
+85.61%
-0.14
Capital Expenditure
—
—
-0.02
+85.61%
-0.14
Financing Cash Flow
56.52
+54.17%
36.66
+38.22%
26.52
-72.44%
96.24
Cash Flow From Continuing Financing Activities
56.52
+54.17%
36.66
+38.22%
26.52
-72.44%
96.24
Net Issuance Payments Of Debt
0.00
+100.00%
-2.50
0.00
-100.00%
98.60
Issuance Of Debt
—
—
0.00
-100.00%
98.60
Repayment Of Debt
0.00
+100.00%
-2.50
0.00
—
Long Term Debt Issuance
—
—
0.00
-100.00%
98.60
Long Term Debt Payments
0.00
+100.00%
-2.50
0.00
—
Net Long Term Debt Issuance
0.00
+100.00%
-2.50
0.00
-100.00%
98.60
Net Common Stock Issuance
58.14
+46.50%
39.69
+46.82%
27.03
0.00
Common Stock Payments
—
—
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
—
0.00
-100.00%
0.51
+79.51%
0.28
Net Other Financing Charges
-1.62
-207.58%
-0.53
+48.13%
-1.02
+61.53%
-2.65
Changes In Cash
-1.10
+96.90%
-35.37
+72.48%
-128.50
-227.46%
-39.24
Beginning Cash Position
29.85
-54.23%
65.22
-66.33%
193.72
-16.84%
232.97
End Cash Position
28.76
-3.67%
29.85
-54.23%
65.22
-66.33%
193.72
Free Cash Flow
-57.62
+20.01%
-72.03
+53.54%
-155.03
-14.43%
-135.48
Interest Paid Supplemental Data
9.69
+21.61%
7.97
+5.52%
7.55
+179.98%
2.70
Change In Interest Payable
0.00
+100.00%
-0.74
-129.48%
2.50
-34.36%
3.80
Common Stock Issuance
58.14
+46.50%
39.69
+46.82%
27.03
0.00
Issuance Of Capital Stock
58.14
+46.50%
39.69
+46.82%
27.03
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category